End-of-life care Not Applicable End-of-life care
Conditions
Interventions
Phase 1: This phase consists of a systematic review of research evaluating medicines access experiences, influences and outcomes within EoL service delivery models.
Phase 2: This phas
Sponsors
University of Southampton
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Phase 2: 1. GPs 2. Community-based palliative care clinical nurse specialists 3. Community nurses 4. Community pharmacists Phase 3: Purposively selected 3 service delivery models in the north of England and 3 in the south, using a sampling frame derived from Phase 2 respondent EoL service models and informed by logic models. Phase 5: Purposive and snowball sampling will be used to identify national experts, including EoL policy, service delivery, professional, and education leads at the Department of Health, NHS England, Health Education England, Royal College of Nursing, Royal College of General Practitioners, Royal Pharmaceutical Society, Health Education England workforce development leads, Clinical Commissioning Group leads for EoL, EoL and Non-Medical Prescribing programme leads from HEIs, charity representatives e.g. Marie Curie, Macmillan Cancer Care, pharmaceutical wholesaler representatives, and key EoL health care professionals. Our PPI co-applicant and Advisory Group PPI members will represent EoL informal carer perspectives.
Exclusion criteria
Exclusion criteria: Those who do not fit the inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Identification of gaps in service provision and deficits in care experienced by patients and carers is assessed using a systematic review of literature (Phase 1), questionnaire survey (Phase 2), patient logs, patient and health care professional interviews, data on service use from patient records within evaluative case studies (Phase 3), and interviews with community pharmacists and pharmaceutical wholesalers and distributors 2. Models of good practice of EoL in service delivery is assessed using a systematic review of literature (Phase 1), questionnaire survey (Phase 2), patient logs, patient and health care professional interviews, data on service use from patient records within evaluative case studies (Phase 3), and interviews with community pharmacists and pharmaceutical wholesalers and distributors | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures. | — |
Countries
England, United Kingdom
Outcome results
None listed